Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2021Yazar
Fankhauser, Christian DanielOldenburg, Jan
Albers, Peter
Algaba, Ferran
Bokemeyer, Carsten
Boormans, Joost L.
Fischer, Stefanie
Fizazi, Karim
Gremmels, Hendrik
Mayor de Castro, Javier
Janisch, Florian
Muilwijk, Tim
Leao, Ricardo
Nicol, David
Nicolai, Nicola
Tandstad, Torgrim
del Pilar Laguna Pes, Maria
Üst veri
Tüm öğe kaydını gösterKünye
Fankhauser, C. D., Oldenburg, J., Albers, P., Algaba, F., Bokemeyer, C., Boormans, J. L. ... del Pilar Laguna Pes, M. (2021). Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European Urology, 80(1), 4-6. https://dx.doi.org/10.1016/j.eururo.2021.02.032Özet
Recent randomized controlled trials have assessed the risksand benefits of thromboprophylaxis in ambulatory cancerpatients receiving chemotherapy and reported a relativerisk reduction of 30–60% in venous thromboembolic events(VTEs) but a doubling of bleeding risk [1–4]. Based on theseresults, the most recent American Society of ClinicalOncology clinical practice guideline update recommendsthromboprophylaxis with apixaban, rivaroxaban, or low-molecular–weight heparin (LMWH) for cancer patientswith a high risk of VTE and low risk of bleeding [5]. Patientswith metastatic germ-cell tumor (mGCT) were under-represented in all trials and thus it is not clear whether thisrecommendation applies to this group, although retrospec-tive data suggests similar efficacy of VTE prophylaxis.